Corestemchemon Inc
166480
Company Profile
Business description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact
Pangyo 255 beongil 24 I & C Building, 2nd Floor
yeonggi-do, Bundang-gu
Seongnam
Seoul13486
KORT: +82 24973711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
376
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,979.40 | 22.00 | -0.24% |
CAC 40 | 7,874.89 | 24.46 | 0.31% |
DAX 40 | 24,465.87 | 225.05 | 0.93% |
Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
FTSE 100 | 9,109.50 | 48.01 | 0.53% |
HKSE | 25,633.29 | 95.22 | 0.37% |
NASDAQ | 21,020.02 | 127.33 | 0.61% |
Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
S&P 500 | 6,358.91 | 49.29 | 0.78% |
S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
SSE Composite Index | 3,605.73 | 23.43 | 0.65% |